Treace Medical (NASDAQ: TMCI) raises 2026 sales view as CCO departs

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Treace Medical Concepts, Inc. announced preliminary first quarter 2026 results and a leadership change. For the three months ended March 31, 2026, preliminary revenue is expected to be in the range of $47.0 million to $47.2 million. Preliminary cash, cash equivalents and marketable securities are expected to total about $51.9 million as of March 31, 2026, up from $48.4 million as of December 31, 2025 and a smaller increase in the first quarter of 2025.

The company updated its full-year 2026 revenue guidance to $202 million to $212 million, slightly raising the low end of the prior outlook to reflect continued case volume growth and headwinds from product and price mix in its expanded bunion portfolio. Treace also disclosed that Chief Commercial Officer Gaetano M. Guglielmino will depart as of April 8, 2026. His responsibilities will be absorbed by existing staff, with the Senior Vice President, Sales reporting directly to the Chief Executive Officer. Guglielmino will serve as an independent consultant through January 31, 2027 under a paid consulting agreement that includes a monthly fee, COBRA premiums, a pro-rated 2026 bonus, apartment rent coverage until lease assignment, and continued vesting of prior equity awards.

8-K Event Classification

3 items: 2.02, 5.02, 7.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Figures

Preliminary Q1 2026 revenue: $47.0 million to $47.2 million Cash and marketable securities: $51.9 million Prior cash balance: $48.4 million +5 more

8 metrics

Preliminary Q1 2026 revenue $47.0 million to $47.2 million Unaudited estimate for three months ended March 31, 2026

Cash and marketable securities $51.9 million Preliminary total as of March 31, 2026

Prior cash balance $48.4 million As of December 31, 2025

Cash increase Q1 2026 Approximately $3.5 million Increase from December 31, 2025 to March 31, 2026

Cash increase Q1 2025 Approximately $0.4 million Increase in the first quarter of 2025

Updated 2026 revenue guidance $202 million to $212 million Full-year 2026 outlook, updated from prior $200M–$212M

Consulting monthly fee $36,666.67 Monthly payment to Gaetano M. Guglielmino under Consulting Services Agreement

Consulting term end date January 31, 2027 End of independent consulting period for former CCO

Key Terms

Regulation FD Disclosure, forward-looking statements, COBRA premiums, equity awards, +2 more

6 terms

Regulation FD Disclosure regulatory

"Item 7.01. Regulation FD Disclosure. Preliminary, Unaudited First Quarter Outlook"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

forward-looking statements regulatory

"This report contains forward-looking statements within the meaning of Section 27A of the Securities Act"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

COBRA premiums financial

"During the term of the Consulting Services Agreement, Mr. Guglielmino will receive (1) a monthly fee ... (2) payment of his COBRA premiums"

equity awards financial

"and (5) continued vesting in previously-granted equity awards in accordance with the terms of such equity awards"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

bunion portfolio technical

"headwinds from demand driven product and price mix shift within the Company’s expanded bunion portfolio"

release of claims regulatory

"Mr. Guglielmino also signed a release of claims in favor of the Company"

Earnings Snapshot

Revenue: $47.0 million to $47.2 million · Guidance included

Q1 2026

Revenue $47.0 million to $47.2 million

Cash, cash equivalents, and marketable securities $51.9 million

Full-year 2026 revenue guidance $202 million to $212 million

Guidance

Full-year 2026 revenue guidance updated to $202 million to $212 million, reflecting continued case volume growth and mix headwinds in the expanded bunion portfolio.

Understanding 8-K Material Events →

04/09/2026 - 07:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 8, 2026

TREACE MEDICAL CONCEPTS, Inc.

(Exact name of registrant as specified in its charter)



Delaware	001-40355	47-1052611
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

100 Palmetto Park Place

Ponte Vedra, Florida 32081

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (904) 373-5940

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	TMCI	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

The information contained in Item 7.01 of this Current Report on Form 8-K under the heading “Preliminary, Unaudited First Quarter Outlook” is incorporated by reference into this Item 2.02. For the avoidance of doubt, no other information contained in Item 7.01 is incorporated by reference into this Item 2.02.

The information provided in Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of the close of business on April 8, 2026, Gaetano M. Guglielmino, Chief Commercial Officer of Treace Medical Concepts, Inc. (the “Company”), will depart from the Company. The Company does not plan to fill the Chief Commercial Officer role. Instead, Mr. Guglielmino’s responsibilities will be assumed by existing employees, and the Senior Vice President, Sales will now report directly to the Chief Executive Officer, John T. Treace. Mr. Guglielmino’s departure from the Company is not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

In order to assist with the transition of his responsibilities, Mr. Guglielmino entered into a Consulting Services Agreement with the Company, effective as of April 9, 2026, that provides, among other things, that Mr. Guglielmino will serve as an independent consultant to the Company through January 31, 2027. During the term of the Consulting Services Agreement, Mr. Guglielmino will receive (1) a monthly fee of $36,666.67, (2) payment of his COBRA premiums, (3) a pro-rated annual target bonus, based on the number of days that he served as an employee during 2026, payable at the same time annual bonuses are paid generally to the Company’s employees, (4) payment for rent on his apartment in Ponte Vedra until such time that the lease is assigned to the Company, and (5) continued vesting in previously-granted equity awards in accordance with the terms of such equity awards. Mr. Guglielmino also signed a release of claims in favor of the Company and a written attestation that his confidentiality, nonsolicitation and noncompetition agreement is in effect and enforceable.

The foregoing description of the Consulting Services Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Services Agreement, which the Company expects to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Item 7.01. Regulation FD Disclosure.

Preliminary, Unaudited First Quarter Outlook

The Company is announcing the following unaudited preliminary estimated results for the three months ended March 31, 2026:

•

Preliminary revenue is expected to be in the range of $47.0 million to $47.2 million.

•

Preliminary cash, cash equivalents, and marketable securities total is expected to be approximately $51.9 million as of March 31, 2026. This represents an increase of approximately $3.5 million from the Company’s balance of $48.4 million as of December 31, 2025 and compares to an increase of approximately $0.4 million in the first quarter of 2025.

The unaudited financial information presented above is based on preliminary estimates as of the date hereof and is subject to the completion of the Company’s financial closing procedures and any adjustments that may result in connection with the Company’s financial closing procedures and finalization of the Company’s financial statements for the first quarter of 2026.

2026 Financial Outlook

The Company is updating its full-year 2026 revenue guidance to $202 million to $212 million. This compares to previous full-year guidance of $200 million to $212 million.

The Company’s updated full-year 2026 guidance reflects continued case volume growth, offset by previously disclosed headwinds from demand driven product and price mix shift within the Company’s expanded bunion portfolio.

The information provided in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s: preliminary first quarter 2026 revenue and cash balance results, and its updated 2026 full-year guidance. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 27, 2026. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	TREACE MEDICAL CONCEPTS, INC.

Date: April 9, 2026	By:	/s/ Mark L. Hair
		Mark L. Hair
		Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What preliminary Q1 2026 results did Treace Medical Concepts (TMCI) report?

Treace Medical expects Q1 2026 revenue of $47.0 million to $47.2 million. It also projects cash, cash equivalents and marketable securities of about $51.9 million as of March 31, 2026, higher than the $48.4 million reported as of December 31, 2025.

How did Treace Medical Concepts (TMCI) update its full-year 2026 revenue guidance?

The company raised its 2026 revenue guidance range to $202 million to $212 million. This updated outlook reflects continued case volume growth, partially offset by previously disclosed demand-driven product and price mix headwinds within Treace Medical’s expanded bunion portfolio.

Which executive is leaving Treace Medical Concepts (TMCI) and when?

Chief Commercial Officer Gaetano M. Guglielmino will depart Treace Medical on April 8, 2026. The company does not plan to refill the Chief Commercial Officer role, and states his departure is not due to any dispute or disagreement regarding operations, policies or practices.

What consulting arrangement did Treace Medical (TMCI) agree with Gaetano M. Guglielmino?

Guglielmino will serve as an independent consultant from April 9, 2026 through January 31, 2027. He will receive a $36,666.67 monthly fee, COBRA premium payments, a pro-rated 2026 target bonus, apartment rent coverage until lease assignment, and continued vesting of prior equity awards.

How did Treace Medical’s cash position change in early 2026?

Treace Medical expects cash, cash equivalents and marketable securities of about $51.9 million on March 31, 2026. This represents an increase of roughly $3.5 million from the $48.4 million balance reported as of December 31, 2025.

What factors influence Treace Medical’s updated 2026 revenue outlook?

The updated 2026 revenue guidance reflects continued case volume growth for Treace Medical. This growth is partly offset by previously disclosed headwinds from demand-driven product and price mix shifts within the company’s expanded bunion portfolio, which affect expected revenue composition.

Filing Exhibits & Attachments

1 document